← Back to Search

Chemotherapy

New Cancer Treatment for Non-Hodgkin's Lymphoma

Phase 2 & 3
Waitlist Available
Led By Raul Ribeiro, MD
Research Sponsored by St. Jude Children's Research Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant must have a histologic diagnosis of a mature B cell lymphoma (e.g., Burkitt lymphoma/leukemia, atypical Burkitt lymphoma, diffuse large B-cell lymphoma, mediastinal large B-cell lymphoma, mature B-cell lymphoma NOS) as defined in the WHO classification.
Participant must be < 22 years of age at the time of diagnosis.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the end of therapy (up to 9 months after enrollment
Awards & highlights

Study Summary

This trial is testing a new cancer treatment for children with B-cell NHL. The new treatment is based on the successful LMB-96 regimen. The trial features prospective biologic and late effect studies.

Who is the study for?
This trial is for children and young adults under 22 years old with a diagnosis of mature B-cell lymphoma, such as Burkitt lymphoma or diffuse large B-cell lymphoma. They must be previously untreated or have had minimal treatment. Those with hepatitis B can participate but won't receive rituximab; HIV-positive patients are excluded from the therapy part but can join biology studies.Check my eligibility
What is being tested?
The study tests modified treatments based on the LMB-96 regimen for various types of mature B-cell lymphomas in children. It's a phase III trial focusing on improving outcomes by studying tumor biology and long-term effects of these therapies.See study design
What are the potential side effects?
Potential side effects may include reactions to chemotherapy like nausea, hair loss, increased infection risk due to weakened immune system, and specific issues related to drugs used (COPAD, CYM etc.), which will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with a specific type of lymphoma (like Burkitt or large B-cell).
Select...
I was diagnosed before turning 22 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the end of therapy (maximum of 9 months after enrollment)
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the end of therapy (maximum of 9 months after enrollment) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Catalog and estimate frequencies of copy number variations in childhood lymphomas
Gene differential profiling of Burkitt Lymphoma (BL) vs. non-BL
Genes
+2 more
Secondary outcome measures
Complete response rate
Event-free survival
Number of possible rituximab-related toxicities
+2 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Group CExperimental Treatment1 Intervention
Any CNS involvement and/or bone marrow involvement ≥ 25% blasts. For CNS involvement one or more of the following applies: Any L3 blasts in CSF Cranial nerve palsy (if not explained by extracranial tumor) Clinical spinal cord compression Isolated intracerebral mass Parameningeal extension: cranial and/or spinal Group C will include the intervention COP, COPADM8, CYVE as follows: Pre-Phase: COP Induction: COPADM8 cycle 1 Induction: COPADM8 Cycle 2 Consolidation: CYVE x 2 cycles and Maintenance
Group II: Group BExperimental Treatment1 Intervention
All cases not eligible for Group A or Group C. (Murphy Stage III and non-CNS Stage IV) Group B will include the intervention COP, COPD M3, CYM as follows: Pre-Phase: COP Induction: COPAD M3 x 2 cycles Consolidation: CYM x 2 cycles.
Group III: Group AExperimental Treatment1 Intervention
Completely resected stage I or completely resected abdominal stage II lesions. Group A will include: COPAD x 2 cycles.

Find a Location

Who is running the clinical trial?

St. Jude Children's Research HospitalLead Sponsor
426 Previous Clinical Trials
5,306,477 Total Patients Enrolled
Raul Ribeiro, MDPrincipal InvestigatorSt. Jude Children's Research Hospital

Media Library

COP (Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT01046825 — Phase 2 & 3
Non-Hodgkin's Lymphoma Research Study Groups: Group A, Group C, Group B
Non-Hodgkin's Lymphoma Clinical Trial 2023: COP Highlights & Side Effects. Trial Name: NCT01046825 — Phase 2 & 3
COP (Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01046825 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants will this research project be testing?

"Unfortunately, this study is no longer looking for patients. It was last updated on September 23rd, 2010. However, there are 2906 trials for lymphoma and 1904 trials for this treatment with open recruitment."

Answered by AI

What are the main aims of this research project?

"The principle aim of this study, which will follow patients for approximately 1 year after they have completed treatment, is to gene profile Burkitt Lymphoma (BL) versus non-BL. Additionally, researchers will secondary outcomes including Event-free survival and number of possible rituximab-related toxicities. Event-free survival is defined as the estimated percentage of patients treated at SJCRH who do not experience a pre-defined set of negative events, including death while in continuous CR, relapse, secondary malignancy, or failure to achieve complete response (CR). The number of episodes and the cumulative incidence throughout the treatment period"

Answered by AI

Can you give me some more information about this treatment's success in other studies?

"There are a total of 1904 active clinical trials researching this treatment, with 422 of them being in Phase 3. Out of the 68566 clinical trial locations, some are based in Bethesda, Maryland."

Answered by AI

What are the usual conditions that doctors use this therapy to improve?

"This new treatment shows potential in the treatment of lung cancers, thyroiditis, and polyangium."

Answered by AI

Can patients sign up for this trial at this time?

"According to the information available on clinicaltrials.gov, this clinical trial is not enrolling patients at this time. The trial was originally posted on 2010-09-09 and was last edited on 2022-09-23. However, there are 4810 other clinical trials that are enrolling patients right now."

Answered by AI
~9 spots leftby Mar 2025